Published in Antimicrob Agents Chemother on May 01, 1995
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 4.89
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother (2000) 2.73
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother (1997) 1.87
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother (1997) 1.83
Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother (1995) 1.75
Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother (1999) 1.48
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother (2001) 1.35
In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother (1996) 1.28
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2002) 1.27
Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother (1998) 1.16
New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents Chemother (1995) 1.11
Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother (2000) 1.10
Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis (1997) 1.04
The Mechanistic Targets of Antifungal Agents: An Overview. Mini Rev Med Chem (2016) 0.75
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother (1987) 7.33
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45
Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother (1993) 4.04
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem (1994) 3.52
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol (1994) 3.51
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother (1994) 2.99
Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A (1994) 2.87
Compounds active against cell walls of medically important fungi. Clin Microbiol Rev (1993) 2.67
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Testing of organisms for susceptibility to triazoles: is it justified? Eur J Clin Microbiol Infect Dis (1989) 2.46
Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis (1994) 2.41
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother (1992) 2.39
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res (1990) 2.08
In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis (1990) 2.06
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS Microbiol Lett (1993) 1.74
Epidemiology and control of fungal infections. Clin Infect Dis (1994) 1.58
Severe candidal infections in neutropenic patients. Clin Infect Dis (1993) 1.14
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 9.10
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother (1980) 9.02
The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci (1974) 7.21
Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother (1982) 5.83
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother (1983) 5.52
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother (1983) 4.25
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem (1994) 3.52
Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies. Antimicrob Agents Chemother (1972) 2.88
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 2.73
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
Guidance for contained field trials of vector mosquitoes engineered to contain a gene drive system: recommendations of a scientific working group. Vector Borne Zoonotic Dis (2008) 2.49
beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis (1992) 2.27
In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother (1998) 2.13
Pregnancy outcome at age 40 and older. Obstet Gynecol (1996) 2.09
Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis (1985) 2.00
Evaluations of children who have disclosed sexual abuse via facilitated communication. Arch Pediatr Adolesc Med (1994) 2.00
A double-blind crossover comparison of topical anesthetics. J Am Dent Assoc (1979) 1.98
Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med (1985) 1.90
International, collaborative experience of 1789 patients having multifetal pregnancy reduction: a plateauing of risks and outcomes. J Soc Gynecol Investig (1996) 1.87
Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother (1997) 1.80
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia (2011) 1.76
Contrast-enhanced cardiac magnetic resonance in a patient with familial isolated ventricular non-compaction. J Cardiovasc Magn Reson (2004) 1.65
In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother (1999) 1.57
Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. Am J Obstet Gynecol (1988) 1.54
High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis? Obstet Gynecol (1990) 1.53
An autopsy case review of 142 nonpenetrating (blunt) injuries of the aorta. J Trauma (1992) 1.50
Ultrasonographic screening for the Down syndrome fetus. Am J Obstet Gynecol (1991) 1.48
Abnormalities of the septum pellucidum in schizophrenia. J Neuropsychiatry Clin Neurosci (1989) 1.45
Difficult airway management of a child impaled through the neck. Paediatr Anaesth (2001) 1.44
Butorphanol and nalbuphine: a pharmacologic comparison. Oral Surg Oral Med Oral Pathol (1985) 1.43
Chondrex: new marker of joint disease. Clin Chem (1998) 1.43
Transabdominal versus transcervical and transvaginal multifetal pregnancy reduction: international collaborative experience of more than one thousand cases. Am J Obstet Gynecol (1994) 1.43
The use of the laryngeal mask airway to facilitate the insertion of a percutaneous tracheostomy. Intensive Care Med (1994) 1.42
Chorionic villus sampling before multifetal pregnancy reduction. Am J Obstet Gynecol (2000) 1.40
Anaesthesia and electroconvulsive therapy (ECT) Anaesthesia (1998) 1.38
Phosphonomycin. V. Evaluation in mice. Antimicrob Agents Chemother (Bethesda) (1969) 1.38
Selective reduction of multifetal pregnancies in the first trimester. N Engl J Med (1988) 1.32
Naloxone-associated morbidity and mortality. Oral Surg Oral Med Oral Pathol (1981) 1.30
The current status of multifetal pregnancy reduction. Am J Obstet Gynecol (1996) 1.27
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev (2001) 1.27
Epidemiology of hepatitis C virus: a study of male blood donors in Saudi Arabia. Transfusion (1994) 1.19
Proenzyme of Manduca sexta phenol oxidase: purification, activation, substrate specificity of the active enzyme, and molecular cloning. Proc Natl Acad Sci U S A (1995) 1.16
Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol (1996) 1.12
Intrauterine intravascular transfusions for severe red blood cell isoimmunization: ultrasound-guided percutaneous approach. Am J Obstet Gynecol (1986) 1.12
Activation of alpha(v)beta3-vitronectin binding is a multistage process in which increases in bond strength are dependent on Y747 and Y759 in the cytoplasmic domain of beta3. Mol Biol Cell (2001) 1.08
Fanconi's anaemia and pregnancy. Br J Haematol (1991) 1.05
A rapid silver impregnation technique for oligodendrocytes, microglia, and astrocytes. J Clin Pathol (1971) 1.05
INABILITY TO PASS PRIMARY ATYPICAL PNEUMONIA TO HUMAN VOLUNTEERS. Science (1943) 1.04
Authorship. Changing authorship system might be counterproductive. BMJ (1997) 1.02
Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet (1998) 1.01
Preadipocyte factor-1 is associated with metabolic profile in severe obesity. J Clin Endocrinol Metab (2011) 1.01
'Vitamin D and cognition in older adults': updated international recommendations. J Intern Med (2014) 1.00
Superior maturation and patency of primary brachiocephalic and transposed basilic vein arteriovenous fistulae in patients with diabetes. J Vasc Surg (1998) 1.00
Non-idiopathic retroperitoneal fibrosis. J Urol (1971) 1.00
Efficacy of second-trimester selective termination for fetal abnormalities: international collaborative experience among the world's largest centers. Am J Obstet Gynecol (1994) 0.99
Microglia in teratomas. Acta Neuropathol (1985) 0.98
Unaltered thyroid function in mice responding to a highly immunogenic thyrotropin receptor: implications for the establishment of a mouse model for Graves' disease. Clin Exp Immunol (1995) 0.97
Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med (1988) 0.96
Twin pregnancies conceived by assisted reproductive techniques: maternal and neonatal outcomes. Obstet Gynecol (1997) 0.96
A 200 kDa protein is associated with haemagglutinating isolates of Moraxella (Branhamella) catarrhalis. FEMS Immunol Med Microbiol (1997) 0.95
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother (1996) 0.95
Attractant resting boxes for rapid collection and surveillance of Aedes aegypti (L.) inside houses. J Am Mosq Control Assoc (1997) 0.95
Gliomyosarcoma. Report of a case of rhabdomyosarcoma arising in a malignant glioma. Acta Neuropathol (1986) 0.95
Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico. Mycopathologia (1989) 0.95
[Infectious fetal diseases. Prevention, prenatal diagnosis, practical measures]. Presse Med (1991) 0.94
Distinct ligand-binding modes for integrin alpha(v)beta(3)-mediated adhesion to fibronectin versus vitronectin. J Biol Chem (2001) 0.94
Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol (1995) 0.93
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother (2006) 0.93
First-trimester growth restriction and fetal aneuploidy: the effect of type of aneuploidy and gestational age. Am J Obstet Gynecol (1997) 0.93
Neuronal inclusions of Parkinson's disease. Mov Disord (1991) 0.93
Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. Antimicrob Agents Chemother (1999) 0.92
Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1996) 0.92
L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. J Antibiot (Tokyo) (1989) 0.92
Letter: New antibacterial agent via photofluorination of a bacterial cell wall constituent. Nature (1973) 0.92
Phosphonomycin. 3. Evaluation in vitro. Antimicrob Agents Chemother (Bethesda) (1969) 0.91
Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem (1998) 0.91
Turner's syndrome and vermiform phlebectasia of the bowel. Trans Am Clin Climatol Assoc (1968) 0.91
Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg (2001) 0.91
Pharmacokinetics of L-671,329 in rhesus monkeys and DBA/2 mice. Antimicrob Agents Chemother (1992) 0.89
Identification of a factor IX/IXa binding protein on the endothelial cell surface. J Biol Chem (1987) 0.89
The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol (2000) 0.89
Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae. Clin Ther (1989) 0.89
Tissue culture adherence and haemagglutination characteristics of Moraxella (Branhamella) catarrhalis. FEMS Immunol Med Microbiol (1999) 0.89
Transmission electron microscopy studies of Moraxella (Branhamella) catarrhalis. FEMS Immunol Med Microbiol (1999) 0.88
Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms. Int Microbiol (2001) 0.88
Occurrence and characterization of plasmids in field isolates of Bordetella bronchiseptica. Am J Vet Res (1982) 0.88